ISNHX Performance — Voya Solution 2030 Portfolio, Class S
Data updated: 2026-08-21
ISNHX returned +7.45% year to date and +14.75% over one year to Jun 2026. Annualised returns are +12.66% over 3 years and +5.91% over 5 years. The fund trailed its Target-Date category average: $100 invested three years ago grew to $143, against $150 for the category, and to $115 over one year, against $118. Volatility over the past three years was 9.14% a year. In the 12 months to Jun 2026 the fund took in a net $5.4M, and assets reached $78.35M.
ISNHX Growth of $100
What $100 invested in Voya Solution 2030 Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Target-Date category average over the same months.
| Period | ISNHX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $115 | $118 |
| 3 years (Jul 2023 – Jun 2026) | $143 | $150 |
| 5 years (Jul 2021 – Jun 2026) | $133 | $143 |
| Since data start (Jul 2019 – Jun 2026) | $164 | $187 |
ISNHX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +7.45% |
| 1 year | +14.75% |
| 3 years (annualised) | +12.66% |
| 5 years (annualised) | +5.91% |
ISNHX Annual Returns
Calendar-year total returns of Voya Solution 2030 Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +7.45% |
| 2025 | +14.30% |
| 2024 | +10.23% |
| 2023 | +15.56% |
| 2022 | −17.87% |
| 2021 | +12.49% |
| 2020 | +13.23% |
| 2019 (Jul–Dec) | +0.06% |
ISNHX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.8% | +1.2% | −4.5% | +5.9% | +3.0% | +0.1% | — | — | — | — | — | — |
| 2025 | +2.5% | +0.2% | −2.3% | +0.3% | +3.0% | +3.3% | +0.6% | +1.8% | +2.1% | +1.3% | +0.4% | +0.3% |
| 2024 | +0.1% | +2.3% | +2.2% | −3.3% | +3.3% | +1.3% | +2.2% | +1.9% | +1.6% | −2.3% | +3.3% | −2.6% |
| 2023 | +6.2% | −2.8% | +2.6% | +0.8% | −1.1% | +3.8% | +2.1% | −1.9% | −3.7% | −2.5% | +7.3% | +4.6% |
| 2022 | −4.3% | −2.4% | +0.2% | −6.5% | +0.2% | −6.2% | +5.7% | −3.5% | −7.9% | +3.6% | +6.2% | −3.4% |
| 2021 | −0.5% | +2.0% | +1.6% | +3.3% | +0.8% | +1.0% | +0.9% | +1.6% | −3.1% | +3.3% | −1.8% | +2.9% |
| 2020 | 0.0% | −0.1% | −0.1% | +0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +9.2% | +3.7% |
| 2019 | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
ISNHX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 9.14%
- 3-year Sharpe ratio: 0.89 (vs 4.5% risk-free rate)
- Best month: +7.32% (Nov 2023)
- Worst month: −4.52% (Mar 2026)
ISNHX Fund Flows
Monthly money in and out of Voya Solution 2030 Portfolio, from SEC Form N-PORT.
- 12-month net flow: $5.4M
- 12-month gross sales (incl. reinvestments): $24.7M
- Sales ÷ redemptions: 1.28×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $1.7M | $1.9M | −$158K |
| May 2026 | $850K | $2.2M | −$1.4M |
| Apr 2026 | $873K | $3.0M | −$2.2M |
| Mar 2026 | $3.3M | $523K | $2.8M |
| Feb 2026 | $1.4M | $2.8M | −$1.3M |
| Jan 2026 | $1.6M | $854K | $743K |
| Dec 2025 | $2.5M | $1.2M | $1.2M |
| Nov 2025 | $2.5M | $326K | $2.1M |
| Oct 2025 | $1.7M | $2.2M | −$550K |
| Sep 2025 | $778K | $1.5M | −$720K |
| Aug 2025 | $4.8M | $1.2M | $3.5M |
| Jul 2025 | $2.7M | $1.5M | $1.3M |
ISNHX Assets Under Management
Net assets of Voya Solution 2030 Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $78.35M |
| 2026-03-31 | $75.27M |
| 2025-12-31 | $74.31M |
| 2025-09-30 | $70.01M |
| 2025-06-30 | $65.92M |
| 2025-03-31 | $60.57M |
| 2024-12-31 | $57.69M |
| 2024-09-30 | $57.65M |
| 2024-06-30 | $55.55M |
| 2024-03-31 | $54.28M |
| 2023-12-31 | $53.45M |
| 2023-09-30 | $47.96M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.